Edgewise Therapeutics’ lead candidate has been shown to reduce levels of a biomarker related to skeletal muscle damage in a ...

PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker ...

Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed ...

Medtronic reported that a patient has completed the first procedure with the latest version of its ingestible camera, used to ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble ...

BeiGene has struck a $150 million deal to license a cancer candidate from CSPC Zhongqi Pharmaceutical Technology, positioning ...

Newron Pharmaceuticals has secured 44 million euros ($46.1 million) in upfront cash from an Eisai subsidiary for select Asia ...

Billion-dollar biotech startup Xaira is expanding its C-suite with some top pharma talent. After wrapping up a 16-year tenure ...

Boundless Bio’s freshman year on the public markets hasn’t been easy, with “modest” layoffs in the summer followed by news ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...